OncoMatch/Clinical Trials/NCT04665206
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Is NCT04665206 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including VT3989 and Nivolumab & Ipilimumab for solid tumor, adult.
Treatment: VT3989 · Nivolumab & Ipilimumab · Osimertinib · Pemetrexed/Carboplatin — This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Tumor Agnostic
Mesothelioma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Required: EGFR l858r
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: tead inhibitor
Lab requirements
Blood counts
adequate organ functions, including the hematopoietic system
Kidney function
adequate organ functions, including the kidneys
Liver function
adequate organ functions, including the liver
Cardiac function
clinically significant cardiovascular disease and prior exposure to cardiotoxic agents; corrected qt (qtcf) interval > 470 msec (using fridericia's correction formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- University of Chicago Medical Center · Chicago, Illinois
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- M Health Fairview University of Minnesota Medical Center · Minneapolis, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04665206 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior tead inhibitor disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR l858r is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify